Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms.
10.12122/j.issn.1673-4254.2023.06.20
- Author:
Dongmei LUO
1
;
Jie LUO
1
;
Hanyin LIANG
1
;
Zherou HE
1
;
Hong CHEN
1
;
Ziyu WEN
1
;
Qiang WANG
1
;
Xuan ZHOU
1
;
Xiaoli LIU
1
;
Na XU
1
Author Information
1. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
essential thrombocythemia;
myeloproliferative neoplasms;
peginterferon-α2b;
polycythemia vera
- MeSH:
Humans;
Retrospective Studies;
Neoplasms;
Alleles;
Plastic Surgery Procedures;
Spleen
- From:
Journal of Southern Medical University
2023;43(6):1029-1034
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy and adverse reactions of peginterferon-α2b for treatment of chronic myeloproliferative neoplasms (MPN).
METHODS:We retrospectively analyzed the data of 107 patients with MPN, including 95 with essential thrombocythemia (ET) and 12 with polycythemia vera (PV), who all received peginterferon-α2b treatment for at least 12 months. The clnical and follow-up data of the patients were analyzed to evaluate the efficacy and adverse reactions of the treatment.
RESULTS:After receiving peginterferon- α2b treatment, both ET and PV patients achieved high hematological remission rates, and the total remission rates did not differ significantly between the two groups (86% vs 78%, P>0.05). In the overall patients, the spleen index decreased by 13.5% (95%CI: 8.5%-18.5%) after the treatment. The patients with hematological remission showed a significantly greater reduction of the total symptom score than those without hematological remission (P < 0.01). The median percentage of JAK2V617F allele load of PV patients decreased from 67.23% (49.6%-84.86%) at baseline to 19.7% (0.57%-74.6%) after the treatment, and that of JAK2V617F-positive ET patients decreased from 48.97% (0.45%-74.24%) at baseline to 22.1% (0.33%-65.42%) after the treatment. Mild adverse reactions (grade 1-2) were observed in both ET and PV groups without significant differences between them. The overall incidence of thrombotic events during the treatment was 2.8% in these patients, and no serious adverse reactions were observed.
CONCLUSION:For patients with chronic myelodysplasia, peginterferon-α2b treatment can achieve a high peripheral blood cell remission rate and maintain a long-term stable state with good effect in relieving symptoms such as splenomegaly. Peginterferon- α2b treatment caused only mild adverse reactions, which can be tolerated by most of the patients.
